ADAM17 and diabetic cardiomyopathy: In addition, the findings suggest that the lncRNA GAS5/miR-21-5p axis may serve as a candidate therapeutic target for diabetic cardiomyopathy [21], while another study found that inhibition of ADAM17 may provide a promising approach [38].